Multicenter, Open-label, Safety and Tolerability Study

NCT01649557 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

244

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: OPC-34712

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.